JAK2 and breast carcinoma: Preclinical studies have shown that specific JAK2 inhibitors can inhibit the growth of tumors in vivo, including pancreatic cancer, colorectal cancer, gastric cancer, liver cancer, lung cancer, ovarian cancer, and breast cancer (Hedvat et al., 2009; Sun et al., 2011).